Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.66 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.66 |
| ▸ | CDK2 | P24941 | 11/20 | 0.61 |
| ▸ | DPP4 | P27487 | 1/20 | 0.61 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.56 |
| ▸ | CDK1 | P06493 | 11/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 11/20 | 0.51 |
| ▸ | CCNA2 | P20248 | 10/20 | 0.51 |
| ▸ | CCNA1 | P78396 | 10/20 | 0.51 |
| ▸ | MGMT | P16455 | 5/20 | 0.49 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2,6-Diaminopurine SCHEMBL24053 | 0.79 | PDPK1 (1.00) | PDPK1GDACDK2DPP4MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL8757979 | 0.78 | PDPK1 (0.96) | PDPK1GDACDK2DPP4MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL27891733 | 0.78 | PDPK1 (0.96) | PDPK1GDACDK2DPP4MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL28206545 | 0.78 | PDPK1 (0.96) | PDPK1GDACDK2DPP4MAP3K5 | |
| Thioguanine SCHEMBL183648 | 0.76 | PDPK1 (0.66) | PDPK1GDACDK2DPP4MAP3K5 | |
| 2,6-Diaminopurine SCHEMBL29143272 | 0.76 | PDPK1 (0.92) | PDPK1GDACDK2DPP4MAP3K5 | |
| SCHEMBL320850 | 0.76 | PDPK1 (0.66) | PDPK1GDACDK2DPP4MAP3K5 | |
| SCHEMBL1336875 | 0.76 | PDPK1 (0.66) | PDPK1GDACDK2DPP4MAP3K5 | |
| SCHEMBL355362 | 0.76 | PDPK1 (0.66) | PDPK1GDACDK2DPP4MAP3K5 | |
| SCHEMBL135690 | 0.76 | CDK2 (1.00) | PDPK1GDACDK2DPP4MAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11597745-B2 | β-modified phosphoric acid compound precursor, β-modified phosphoric acid compound, reaction inhibitor and medicine containing the same, and method for inhibiting reaction | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2023-03-07 | — | — | US | claimed |
| EP-1212339-B1 | 2'-O-ACETAMIDO MODIFIED MONOMERS AND OLIGOMERS | ISIS PHARMACEUTICALS INC (US) | 2008-12-31 | — | — | EP | claimed |
| US-20070179100-A1 | Protected monomers | ALNYLAM PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | claimed |
| EP-1625138-A2 | PROTECTED MONOMERS | Alnylam Pharmaceuticals Inc. (US) | 2006-02-15 | — | — | EP | claimed |
| EP-1499627-A2 | NUCLEASE RESISTANT CHIMERIC OLIGONUCLEOTIDES | ISIS Pharmaceuticals, Inc. (US) | 2005-01-26 | — | — | EP | claimed |
| WO-2004094345-A2 | PROTECTED MONOMERS | ALNYLAM PHARMACEUTICALS INC. (US) | 2004-11-04 | — | — | WO | claimed |
| US-20040033973-A1 | Compounds and oligomeric compounds comprising novel nucleobases | ISIS PHARMACEUTICALS, INC. | 2004-02-19 | — | — | US | claimed |
| US-6649750-B1 | Nucleoside linked to a support through heterocyclic base and amide bond; deblocking/deprotecting; capping/oxidizing; purity; reduced levels of byproducts containing abasic sites | ISIS PHARMACEUTICALS, INC. | 2003-11-18 | — | — | US | claimed |
| US-20030207804-A1 | Modified peptide nucleic acids | ISIS PHARMACEUTICALS, INC. | 2003-11-06 | — | — | US | claimed |
| US-6639062-B2 | Oligonucleotides which elicit ribonuclease for cleavage in complementary nucleic acid strand, having increased binding affinity/nuclease resistance; for medical diagnosis, gene therapy | ISIS PHARMACEUTICALS, INC. | 2003-10-28 | — | — | US | claimed |
| US-20030175906-A1 | Nuclease resistant chimeric oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2003-09-18 | — | — | US | claimed |
| US-20030158403-A1 | Nuclease resistant chimeric oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2003-08-21 | — | — | US | claimed |
| WO-2003004602-A2 | NUCLEASE RESISTANT CHIMERIC OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2003-01-16 | — | — | WO | claimed |
| WO-2002097134-A2 | MODIFIED PEPTIDE NUCLEIC ACID | ISIS PHARMACEUTICALS, INC. (US) | 2002-12-05 | — | — | WO | claimed |
| EP-1212339-A4 | 2'-O-ACETAMIDO MODIFIED MONOMERS AND OLIGOMERS | ISIS PHARMACEUTICALS INC (US) | 2002-09-18 | — | — | EP | claimed |
| EP-1212339-A1 | 2'-O-ACETAMIDO MODIFIED MONOMERS AND OLIGOMERS | ISIS PHARMACEUTICALS, INC. (US) | 2002-06-12 | — | — | EP | claimed |
| US-6271358-B1 | FOR INHIBITING SPECIFIC GENE EXPRESSION; HAVING ENHANCED HYBRID BINDING AFFINITY AND/OR INCREASED NUCLEASE RESISTANCE | ISIS PHARMACEUTICALS, INC. | 2001-08-07 | — | — | US | claimed |
| WO-2001014400-A1 | 2'-O-ACETAMIDO MODIFIED MONOMERS AND OLIGOMERS | ISIS PHARMACEUTICALS, INC. (US) | 2001-03-01 | — | — | WO | claimed |
| US-6147200-A | NUCLEOSIDES FOR SOLID PHASE SYNTHESIS OF OLIGONUCLEOTIDES HAVING INCREASED NUCLEASE RESISTANCE AND BETTER BINDING AFFINITY; DIAGNOSIS; ANTISENSE THERAPY | ISIS PHARMACEUTICALS, INC. (US) | 2000-11-14 | — | — | US | claimed |
| US-6127533-A | SPECIFICALLY HYBRIDIZABLE WITH A SELECTED SEQUENCE OF RNA OR DNA; DIAGNOSIS OF DISEASES | ISIS PHARMACEUTICALS, INC. (US) | 2000-10-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040033973-A1 | Compounds and oligomeric compounds comprising novel nucleobases | NT5C3B, NUDT1, NME4 | PDPK1 3710/4885GDA 354/4885CDK2 773/4885 |
| US-20030158403-A1 | Nuclease resistant chimeric oligonucleotides | RNASE1, DIS3, DCLRE1B | PDPK1 4222/4885GDA 276/4885CDK2 2894/4885 |
| US-20030207804-A1 | Modified peptide nucleic acids | NGLY1, PARN, NPPA | PDPK1 3943/4885GDA 555/4885CDK2 3658/4885 |
| US-20030175906-A1 | Nuclease resistant chimeric oligonucleotides | DIS3, RNASE1, DCLRE1B | PDPK1 4486/4885GDA 270/4885CDK2 2900/4885 |
| US-11597745-B2 | β-modified phosphoric acid compound precursor, β-modified phosphoric acid compound, reaction inhibitor and medicine containing the same, and method for inhibiting reaction | PPM1A, PPM1G, PPM1F | PDPK1 116/4885GDA 3789/4885CDK2 225/4885 |
| US-20070179100-A1 | Protected monomers | PCNA, POLN, PARP1 | PDPK1 4540/4885GDA 279/4885CDK2 2995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.